Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

Study limitation reported by the research below: “This trial was open-label with no placebo or active comparator arm, which limits interpretation of safety findings relative to background therapy alone.”